Welcome to our dedicated page for Oragenics news (Ticker: OGEN), a resource for investors and traders seeking the latest updates and insights on Oragenics stock.
Oragenics, Inc. (NYSE American: OGEN) is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology. News related to Oragenics often centers on the progress of its lead intranasal drug candidate, ONP-002, which is being advanced for the treatment of concussion and mild traumatic brain injury, as well as broader developments in its intranasal platform for neurological disorders.
Investors and followers of OGEN can use this news feed to track company announcements about clinical milestones, such as Human Research Ethics Committee approval in Australia, selection of Southern Star Research as Clinical Research Organization for the Phase IIa ONP-002 trial, and updates on anticipated Phase IIa and Phase IIb studies. Oragenics’ press releases also cover manufacturing and operational agreements, including its cGMP production partnership with Sterling Pharma Solutions to supply ONP-002 for clinical development.
Another recurring theme in Oragenics news is strategic and financial activity. The company has reported public offerings of Series H Convertible Preferred Stock and Warrants, at-the-market equity sales, and related steps taken to restore and maintain compliance with NYSE American stockholders’ equity requirements. These updates provide context on how Oragenics is funding its clinical programs and strengthening its balance sheet.
In addition, Oragenics issues news about pipeline expansion and partnerships, including its collaboration with Receptor.AI, an artificial intelligence–driven drug profiling company, aimed at accelerating development of additional pharmaceutical candidates for brain health. The company also announces its participation in industry conferences and investor events, where it presents its intranasal concussion program and broader neurological platform. Readers interested in OGEN can follow this page for ongoing disclosures directly sourced from company press releases and related regulatory communications.
Oragenics (NYSE American: OGEN) provided a Q2 2025 shareholder update highlighting progress in developing ONP-002, its lead candidate for concussion treatment. The company secured a $16.5 million capital raise through Series H Convertible Preferred Stock and Warrants, with net proceeds of $15.2 million.
Key operational achievements include HREC approval in Australia, appointment of Southern Star Research as CRO, and a cGMP manufacturing agreement with Sterling Pharma Solutions. The company demonstrated financial discipline with a 50% reduction in R&D expenses and 8% decrease in administrative costs.
Oragenics plans to initiate Phase IIa trials in Q3 2025, followed by IND submission to FDA for Phase IIb trials in Q3-Q4 2025. The company targets the $8.9 billion global concussion market by 2027, aiming to become the first FDA-approved pharmacological treatment for concussion.
Oragenics (NYSE American: OGEN) has selected Southern Star Research as its Clinical Research Organization (CRO) for the upcoming Phase IIa clinical trial of ONP-002, a drug candidate for concussion treatment. The trial will be a randomized, double-blind, placebo-controlled study evaluating ONP-002 in adults with mild traumatic brain injury (mTBI).
The company has already secured Human Research Ethics Committee (HREC) approval and chosen Australia for the trial due to its streamlined regulatory process, experienced trial sites, and R&D tax incentive benefits. ONP-002 is a proprietary intranasal neurosteroid that has shown promising results in preclinical models, including reduced brain inflammation and improved cognitive function.
Oragenics (NYSE American: OGEN) has secured a manufacturing agreement with Sterling Pharma Solutions for the GMP production of ONP-002, its lead drug candidate for concussion treatment. The U.S.-based manufacturing partnership will support Oragenics' planned Phase IIb clinical trials expected to begin in 2026.
The collaboration with Sterling's facility in Cary, North Carolina, represents a crucial milestone in Oragenics' development strategy, ensuring domestic production capabilities for their upcoming clinical and regulatory efforts. The trials will evaluate ONP-002's early efficacy in patients with mild traumatic brain injury (mTBI), addressing a condition that currently lacks FDA-approved pharmacological treatments.
Oragenics (NYSE American: OGEN) has successfully closed a public offering, raising $16.5 million through the issuance of 660,000 shares of Series H Convertible Preferred Stock and Warrants. Each unit, comprising one preferred share and one warrant, was priced at $25.00. The warrants could potentially generate an additional $16.5 million if fully exercised.
The preferred stock is convertible at $2.50 per common share, and the warrants expire in five years. The proceeds will primarily fund the development of ONP-002, an intranasal drug candidate for treating concussion, along with repaying a $3 million bridge note and supporting general corporate purposes.
Oragenics (NYSE American: OGEN), a company developing intranasal pharmaceuticals for neurological disorders, has announced the pricing of a public offering of up to 800,000 shares of Series H Convertible Preferred Stock and Warrants. The combined offering price is set at $25.00 per unit, with the potential to raise up to $20 million in gross proceeds.
The Preferred Stock is convertible into common stock at $2.50 per share, and the Warrants allow purchase of additional Preferred Stock at $25.00 per share. The offering is expected to close around July 2, 2025. Dawson James Securities is serving as the sole placement agent.
The company plans to use the proceeds to fund its ONP-2 concussion clinical trials, related R&D activities, repay a $3 million bridge note, and for working capital and general corporate purposes.
Oragenics (NYSE: OGEN) has announced a 1-for-30 reverse stock split of its common stock, effective June 3, 2025. Following the split, every 30 pre-split shares will automatically combine into one new share, with fractional shares rounded up to the nearest whole share. The reverse split was approved by the Board on May 27, 2025, after receiving shareholder authorization for a split ratio between 1-for-5 and 1-for-50.
The company's stock will continue trading under the symbol "OGEN" with a new CUSIP number (684023 609). The split will not affect the par value of common stock or authorized but unissued shares. CEO Janet Huffman stated that this move aims to strengthen their capital markets presence and attract long-term, quality-focused investors.
Oragenics (NYSE: OGEN) has received approval from Australia's Human Research Ethics Committee (HREC) to begin a Phase II clinical trial for ONP-002, its intranasal neuroprotective therapy for treating concussions (mild traumatic brain injury). Patient enrollment could start as early as Q2 2025, with trials conducted in level 1 trauma emergency departments across Australia and New Zealand.
ONP-002 is administered intranasally and has shown promising results in preclinical models, demonstrating ability to reduce inflammation, oxidative stress, and brain swelling associated with concussion. The drug has already completed Phase I trials, proving to be safe and well-tolerated.
Oragenics (NYSE: OGEN) has announced a management update webinar scheduled for May 20, 2025, at 4:00 PM ET. The webinar will focus on the company's lead program ONP-002, a proprietary intranasal neuroprotective therapy for treating mild traumatic brain injury (mTBI) or concussion. The event will feature presentations from CEO Janet Huffman, Chief Clinical Officer Dr. Frank Peacock, and Dr. James Kelly.
ONP-002 is currently advancing in its Phase IIa clinical program. The drug is administered intranasally for direct brain delivery while minimizing systemic exposure. Preclinical studies have shown ONP-002's ability to reduce inflammation, oxidative stress, and brain swelling post-head injury, while Phase I trials demonstrated safety and tolerability.
Oragenics (NYSE American: OGEN) announced its participation in the 15th Annual Traumatic Brain Injury Conference in Boston, MA on May 5-6, 2025. The company's Chief Clinical Officer, Dr. W. Frank Peacock, will present updates on the HeadSMART II trial, one of the largest U.S. emergency department biomarker discovery studies for mild traumatic brain injury (mTBI).
The study, expected to enroll over 2,000 patients within the next year, is conducted in collaboration with BrainBox Solutions. This partnership aims to develop a comprehensive test-to-treat platform combining BrainBox's diagnostics with Oragenics' intranasal therapeutic candidate, ONP-002.
The conference brings together leaders from academia, industry, government, and military to discuss advances in TBI research and clinical care, focusing on diagnosis, treatment, and long-term outcomes for TBI survivors.